An interventional study of Virtual Care in Acute Kidney Injury, sponsored by University of Calgary. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of Calgary · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Acute Kidney Injury with a site in Canada — 19 open to participants now, 22 under way, 1 of them phase 3. Acute Kidney Injury · Canada.
Among the 83 studies in Acute Kidney Injury with a site in Canada, this one is the 14th largest by planned enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2024, is one of 21 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 73rd registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →19 of the 83 studies in Acute Kidney Injury with a site in Canada are open now. Recruiting first, the newest first:
Uppsala University · Sites in Canada, Australia, Brazil and 7 more countries
Ages 0–16
AstraZeneca · Sites in Canada, United States, Argentina and 11 more countries
Ages 18–80
Matthew James · Sites in Canada
Ages 18+
Hamilton Health Sciences Corporation · Sites in Canada
Ages 18+
University of California, San Francisco · Sites in Canada, United States
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 18 · Phase 3 9 · Phase 4 6
First in 1996; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 354 is above the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 137 across the 54 interventional studies, 500 across the 29 observational. Of the 52 that completed or were terminated, 10 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 83 have an industry lead sponsor. The 10 most frequent:
University of Calgary is the lead sponsor of 704 studies on the registry; 197 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.
University of Calgary has 4 studies filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
10 of the studies in Acute Kidney Injury with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06337838Phase 3Hamilton Health Sciences CorporationBleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial | 2027-02 |
| NCT06446739University of AlbertaLoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM) | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT04936607Montreal Heart InstituteImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions | 2027-01-30 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 10 to your calendar (.ics) → With an account.
Among the 83 studies in Acute Kidney Injury with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Method: Randomized Controlled Trial Study Duration: 3 Years Study Centre(s) University of Calgary and University of Alberta Objectives: To fill care gaps by implementing strategies to reduce length of hospital stay, readmission rates, and improve long-term outcomes after Acute Kidney Injury (AKI). Number of Participants: Three Hundred and fifty four (n=354) Diagnosis and Main Inclusion Criteria: Hospitalized adults with AKI at high risk of hospital readmission or death
Study Intervention: Multi-component Digital Health Solutions, including:
Background and Rationale
Acute kidney injury (AKI) is a common and serious complication in hospitals. A major care gap for survivors of AKI is the fragmentation of care that exists as they transition from the hospital to their home. This contributes to a high risk of adverse long-term outcomes, including prolonged hospitalization, high rates of readmission, cardiovascular events, infections, progression to chronic kidney disease (CKD), kidney failure requiring dialysis, and death.
To address this challenge, the investigators are implementing multi-component digital health solutions including Computerized Clinical Decision Support (CDS) and Digital Remote Patient Monitoring (dRPM) through Virtual Care (VC) programs in Alberta to reduce length of hospital stay and readmission rates and improve long-term outcomes after AKI.
Evidence of the effectiveness of the two digital health solutions is available from Alberta and international clinical trials. Our team previously implemented a computerized CDS intervention for AKI risk assessment and prevention and achieved improved AKI prevention and reduced AKI incidence after cardiac procedures across the province. The investigators will use a similar approach to identify high risk patients with AKI and provide recommendations to improve the quality of their care, which is well suited to the evolving digital health infrastructure in Alberta.
Providing hospital-level care at home through Virtual Care (VC) teams has been shown to reduce mortality and readmission rates. Alberta's VC program have existed in both Edmonton and Calgary since 2018 and have reported lower readmission rates, Emergency Department (ED) visits and use of Emergency Medical Services than observed with usual care. Patients reported that the program helped them regain their independence and function. Alberta's VC programs have implemented dRPM technology, which has been further associated with fewer days in hospital and emergency department visits. Patients reported better quality of care using this technology. The framework for dRPM and complex care planning is already in place in Alberta's Virtual Care programs. The investigators intend to utilize these programs to improve transitions of care through early facilitated discharge and enhanced follow-up of patients with AKI at high risk of hospital readmission, who require frequent monitoring and more intensive care strategies during this vulnerable period of transition in care.
Research Question and Objectives
The investigators will evaluate implementation initially in a Vanguard phase to establish feasibility and acceptability of the intervention, followed by an evaluation of implementation and effectiveness of the intervention in a larger Multicenter Randomized Controlled Trial (RCT). High risk patients with AKI and a predicted risk of readmission or death ≥20% will be identified using a Best Practice Alert (BPA) in Connect Care and participants will be randomized to care with or without virtual monitoring through the VC programs. All patients will receive the same baseline interventions refined in the Vanguard phase, while the intervention arm will additionally receive VC with dRPM following discharge.
High risk patients in the intervention arm will be navigated through the transition of care pathway by a trained nurse navigator. Patients will receive dRPM kits, and biometric data will be automatically uploaded to the web-based monitoring platform and reviewed by the nurse navigator. Patients will receive regular virtual assessments via telephone or videoconferencing (via the tablet) after in-patient discharge. Blood tests will be drawn at home by community paramedics as deemed necessary by the clinical team to assess kidney function and monitor for complications of AKI. Should concerns be identified that warrant in-person assessment, paramedic care teams will be sent for assessment and/or intervention. Upon completion of the intervention patients will be assessed for readiness to move to the subacute arms of the program and return to their primary care provider. If ongoing nephrologist or other specialist care is required, the nurse navigator will ensure appropriate follow up is arranged.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive virtual care through Virtual Home Hospital programs in Alberta for their hospital to home transition of care.
Other: Virtual Care
Participants will be discharged as per usual care practices from hospital to their home.
Participants will go through Virtual hospital programs following the processes established by these programs in Alberta.
the number of days alive out of hospital
the number of days alive out of hospital
Time frame: Up to 45 days from the date of randomization
the time as inpatient in hospital
the time as inpatient in hospital
Time frame: Up to 45 days from the date of randomization
death
death records from health administrative data.
Time frame: from the date of randomization up to 45 days, or date of death from any cause, whichever came first,
hospital readmission
hospital readmission records from health administrative data.
Time frame: Up to 45 days from the date of randomization
Emergency Department visits
Emergency Department visit records from health administrative data.
Time frame: Up to 45 days from the date of randomization
Estimated Glomerular Filtration (eGFR)
eGFR
Time frame: At 90 days after the date of randomization
Urine Albumin Creatinine Ration (ACR)
ACR laboratory test
Time frame: At 90 days after the date of randomization
total number of physician visits
total number of physician visits
Time frame: Up to 45 days from the date of randomization
number of physician visits by specialty
primary care vs. non-primary care
Time frame: Up to 45 days from the date of randomization
Changes to medication prescription
Changes to medication prescription (including starting, stopping, or dose adjustment) of an Angiotensin-Converting Enzyme Inhibitors (ACEI)/Angiotensin receptor blockers (ARB), diuretic, SGLT2 inhibitor, or NSAID or administration of IV fluid
Time frame: Up to 45 days from the date of randomization
laboratory testing
Number of creatinine/eGFR, electrolytes, and urine protein quantification
Time frame: Up to 45 days from the date of randomization
patient experience care transition measure
Online Survey
Time frame: At 45 days after the date of randomization
Euro Qol- 5 Dimension (EQ5D)
Online Survey to assess quality of life mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from "no problems" to "extreme problems
Time frame: At 45 days after the date of randomization
Started Aug 2024 (actual). Primary completion is estimated for Jun 2027, 34 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 34 months is above that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Aug 2026 → Jun 2027 and completion Oct 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.